PMN310 interim Phase 1b safety and biomarker signals reported
PMN310, a differentiated antibody targeting toxic amyloid beta oligomers, showed strong interim safety and biomarker signals in a Phase 1b Alzheimer's study. Final results are expected in Q1; PMN is funded through 2027.
PMN310, a differentiated antibody targeting toxic amyloid beta oligomers, showed interim safety and biomarker signals in a Phase 1b Alzheimer's study, with final results expected in Q1. The company said it is well-funded through 2027 and continues to advance its pipeline while exploring partnerships and other options.